Literature DB >> 18637036

GAD65 IgG autoantibodies in stiff person syndrome: clonality, avidity and persistence.

G Skorstad1, A L Hestvik, P Torjesen, K Alvik, F Vartdal, B Vandvik, T Holmøy.   

Abstract

BACKGROUND AND
PURPOSE: Persistent intrathecal production of IgG autoantibodies against glutamic acid decarboxylase 65 (GAD65 IgG) and oligoclonal IgG of undetermined specificity has been reported in stiff person syndrome (SPS).
METHODS: To chart the avidity and clonal patterns of GAD65 IgG, we performed scatchard plot of binding characteristics and isoelectric focusing-immunoblot of cerebrospinal fluid (CSF) and serum from five SPS patients.
RESULTS: Oligoclonal GAD65 IgG bands, predominantly restricted to the IgG1 subclass, were detected in CSF and serum in all patients. The distribution of GAD65-specific IgG bands in serum and CSF revealed intrathecal synthesis of oligoclonal GAD65 IgG in all five patients, whilst radioimmunoassay demonstrated intrathecal synthesis of GAD65 IgG in four. The binding avidity of GAD65 IgG from CSF was more than 10 times higher than in serum in two of the patients but did not differ substantially in the remaining three. These differences were not related to symptom severity. The pattern of oligoclonal GAD65 IgG bands in CSF and serum in three patients examined remained unchanged for up to 7 years after symptom debut.
CONCLUSION: This study confirms the persistent systemic and intrathecal production of GAD65-specific IgG in SPS, and further shows that this immune response is oligoclonal and mediated by a stable population of affinity maturated B cell clones.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637036     DOI: 10.1111/j.1468-1331.2008.02221.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  3 in total

Review 1.  Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians.

Authors:  Elisabeth Chroni; Alexandra Monastirli; Dionysios Tsambaos
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

2.  Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.

Authors:  M Chéramy; C S Hampe; J Ludvigsson; R Casas
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

3.  Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity.

Authors:  Nuria Gresa-Arribas; Helena Ariño; Eugenia Martínez-Hernández; Mar Petit-Pedrol; Lidia Sabater; Albert Saiz; Josep Dalmau; Francesc Graus
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.